Organ Transplantation Clinical Trial
Official title:
A Single Centre, Prospective, Open-Label, Parallel Group, Randomized Study to Compare the Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, CellCept) and Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated With Calcineurin Inhibitors
The purpose of the study is to assess the gastrointestinal tolerability of EC-MPS compared to MMF in maintenance transplant patients on a calcineurin inhibitor regimen, who require MMF dose reductions of 25% or more due to GI complications. The tested hypothesis is that the EC-MPS treatment is superior to the MMF therapy in terms of tolerability and that patients on the EC-MPS formulation will be able to tolerate higher doses compared to those on MMF.
The use of mycophenolate mofetil (MMF) in combination with a calcineurin inhibitor (CNI: tacrolimus or cyclosporine) has been shown to improve graft survival in renal, cardiac and liver transplantation patients. However, its use has been associated with significant side effects, including gastrointestinal complications, causing dose reductions, interruption or termination of the therapy. An alternate formulation: enteric coated mycophenolate sodium (EC-MPS) was designed to alleviate the severity of upper gastrointestinal side effects. Several trials detailed in the protocol suggest a benefit in GI related health following conversion from MMF to EC-MPS, however we believe that robust data are lacking. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00987103 -
Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT03699839 -
Reducing the Burden of Influenza After Solid-Organ Transplantation
|
Phase 2/Phase 3 | |
Completed |
NCT01633424 -
The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT)
|
||
Completed |
NCT01254955 -
Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients
|
N/A | |
Completed |
NCT00948883 -
Study of Cancers After Solid Organs Transplants
|
N/A | |
Recruiting |
NCT02314949 -
Leuven Tolerogenic Protocol for Intestinal Transplantation
|
N/A | |
Recruiting |
NCT01283295 -
Immune Monitoring and Assay Development in Organ Transplant Recipients
|
||
Not yet recruiting |
NCT03861962 -
Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
|
||
Completed |
NCT01123187 -
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
|
N/A | |
Completed |
NCT00213304 -
The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation
|
Phase 3 | |
Completed |
NCT01515072 -
Remote Ischemic Preconditioning in Neurological Death Organ Donors
|
N/A | |
Completed |
NCT00904579 -
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
|
||
Recruiting |
NCT04687865 -
Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)
|
||
Completed |
NCT02852902 -
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.
|
||
Completed |
NCT05685888 -
Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation
|
||
Recruiting |
NCT00792064 -
Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation
|
N/A | |
Completed |
NCT00734396 -
Mesenchymal Stem Cells and Subclinical Rejection
|
Phase 1/Phase 2 | |
Completed |
NCT00286871 -
Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen
|
Phase 1 | |
Recruiting |
NCT03997253 -
Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management
|
N/A | |
Recruiting |
NCT01256931 -
Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients.
|
N/A |